Munich’s biotech hub: Inside one of Europe’s leading life sciences ecosystems
Munich has long been recognized as one of Germany’s scientific powerhouses, but in recent years it has also emerged as one of Europe’s most dynamic biotech and life sciences ecosystems. Bringing together leading academic institutions, multinational pharmaceutical companies, cutting-edge startups, and strong investment, the region has created an environment that consistently translates scientific research into commercial innovation.
CHMP backs Minoryx’s rare disease drug two years after rejection
Why it matters: The comeback gives Minoryx a potential route to the first pharmacological treatment for cerebral adrenoleukodystrophy (cALD), but only in a narrowly defined group of young patients.
Moa Technology raises $30m to advance novel modes of action in weed management
UK-based Moa Technology has raised a £22.2 million ($29.6 million) Series C round to further advance its discovery platf…
China’s Rural Investment, Consumption Register Steady Growth In H1
July 2026, Beijing: China’s investment and consumption in rural areas achieved solid growth in the first half (H1)…
Sanofi drops eczema drug from $1.1B Kymab deal
Why it matters: Amlitelimab was the principal asset behind Sanofi’s $1.1 billion acquisition of Cambridge, UK-based Kymab in 2021 and had once been viewed as a potential successor to its blockbuster eczema drug Dupixent.
🎥 Can editing the ‘dark genome’ make crops more heat tolerant?
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Plantik Biosciences.] Can editing the so-called “da…
新型间苯二酰胺类杀虫剂—氟环炔虫二酰胺
氟环炔虫二酰胺（pynflanilide）是启农生物2024年研发的新型间苯二酰胺类杀虫剂，其可看作是在格力高的基础上通过中间体衍生化法优化得到的。其合成本质是将格力高（溴虫氟苯双酰胺）的苯甲酸换成4-(环丙基炔基)苯甲酸。环丙基炔基的引入重构了分子构象，理论上对于某些对格力高产生微抗性的部分群体仍旧保持高效。但由于苯环和多氟取代都是强疏水基团，在引入环丙基，可能导致整体的log P偏高，有助于药物穿透昆虫体壁的同时也会牺牲部分在植物体内的代谢能力，同时炔基环丙基的引入可能影响制剂的稳定性，这对制剂配方技术也是一个考验。报道显示氟环炔虫二酰胺对蚜虫高效。
Iceland-based Synaptiq launches with Nobias’ rare disease drug
The Iceland-headquartered company has renamed Nobias’ NB-001 programme SYN-001 and plans to test it in a Phase 2b trial for neuropsychiatric symptoms associated with 22q11.2 deletion syndrome, also known as DiGeorge syndrome.
🎥 Inside Faraday Earth’s bid to make cheap green ammonia without Haber-Bosch
[Disclosure: AgFunderNews’ parent company AgFunder is an investor in Faraday Earth] Can a container-sized plasma reactor…
North Dakota Welcomes Travelers for Peak Sunflower Season
July 2026, Bismarck: Every summer, North Dakota’s landscape transforms into brilliant shades of gold as sunflower …